Search clinical trials for: mycophenolate sodium

Total 10987 results

Novartis

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Renal Transplantation

Switzerland
Novartis

Completed

A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.

Kidney Transplantation
Novartis

Completed

Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant

Kidney Transplantation

Brazil
Novartis

Completed

Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients

Renal Transplantation
Novartis

Completed

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients

Kidney Transplantation

Switzerland
Novartis

Completed

Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Maintenance Kidney Transplant

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients

Kidney Transplantation

United States
Novartis Pharmaceuticals

Completed

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Kidney Transplantation

Germany, Switzerland
University of Saskatchewan

Withdrawn

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring (COBACAM)

Cardiovascular Disease | Kidney Transplantation | Kidney Transplant Recipients | Cardiovascular Outcomes

Canada
Gaetano Ciancio

Completed

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

Transplant; Failure, Kidney

United States
Novartis

Completed

Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy

Liver Transplantation | Kidney Transplantation

Switzerland
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients

Renal Transplant

China
Hospital Universitari Vall d'Hebron Research Institute

Completed

Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations

Systemic Lupus Erythematosus

Spain
University of Utah

Completed

Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

Kidney Transplantation

United States
Novartis Pharmaceuticals

Completed

Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms (PROGIS)

Kidney Transplantation | GI Symptoms Severity

Malaysia
University of California, Los Angeles
Novartis

Completed

Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®

Signs and Symptoms, Digestive | Gastrointestinal Lesions

United States
Associação Médico Espírita de Botucatu

Completed

Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients

Cytomegalovirus Infections | Disorder Related to Renal Transplantation
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients

Liver Transplantation

Taiwan
University of Sao Paulo General Hospital

Unknown

Renal Transplantation in the Elderly - nEverOld Study

Renal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)

Brazil
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients

Kidney Transplantation

Germany
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS) (AUC-MPA)

Renal Transplantation

Brazil
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Hospital do Rim e Hipertensão

Completed

Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate

Cytomegalovirus Infection | Transplant; Complication, Rejection | Renal Transplant Failure

Brazil
Boehringer Ingelheim

Completed

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Healthy

Germany
Novartis Pharmaceuticals

Completed

Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study. (MAXIMIZA)

Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft

Spain
East Carolina University
Novartis Pharmaceuticals

Completed

Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)

Transplant; Failure, Kidney

United States
Chulalongkorn University
Clinical Research Collaborative Network; Health Intervention and Technology...

Terminated

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis (CONTROL)

Lupus Nephritis

Thailand
Novartis Pharmaceuticals

Terminated

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

Renal Transplantation

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

Chronic Renal Failure

Israel
Novartis Pharmaceuticals

Completed

Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

Renal Function

Denmark, Norway, Sweden
Novartis Pharmaceuticals

Completed

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) (IDEALE)

Renal Transplantation

France
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers

Healthy
National Institute of Allergy and Infectious Diseases...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Withdrawn

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

Diabetes Mellitus, Type I
Novartis

Completed

Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

Renal Transplantation

Switzerland, Germany
Novartis Pharmaceuticals

Completed

SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus

Renal Transplanted Recipients

Australia
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Kidney de Novo Transplant
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients

Heart Transplantation

United States, Australia, Argentina, Canada
Novartis Pharmaceuticals

Completed

An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients

Kidney Transplant Recipients
Novartis Pharmaceuticals

Terminated

MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive

De Novo Kidney Transplant
Novartis Pharmaceuticals

Completed

Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107

Renal Transplant
Novartis Pharmaceuticals

Completed

A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)

Renal Transplantation
Novartis Pharmaceuticals

Completed

Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

Renal Transplantation
Armin Goralczyk

Unknown

Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation (CILT)

Liver Transplantation | Chronic Renal Insufficiency

Germany
Novartis Pharmaceuticals

Completed

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

Renal Transplantation

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

Lupus Nephritis

France, Spain, Colombia, Hungary, Italy, Germany, Greece, Taiwan, United Kingdom
Novartis Pharmaceuticals

Completed

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants

Kidney Transplantation | Pancreas Transplantation

Germany
Novartis

Completed

Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients (OLYMPE)

Kidney Diseases

Switzerland
Novartis Pharmaceuticals

Completed

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate

Autoimmune Disease

Germany
Novartis

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients

Renal Transplantation

France
Novartis Pharmaceuticals

Terminated

Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients

Kidney Transplantation

Italy

3

Subscribe